SG11202010841QA - Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides - Google Patents
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosidesInfo
- Publication number
- SG11202010841QA SG11202010841QA SG11202010841QA SG11202010841QA SG11202010841QA SG 11202010841Q A SG11202010841Q A SG 11202010841QA SG 11202010841Q A SG11202010841Q A SG 11202010841QA SG 11202010841Q A SG11202010841Q A SG 11202010841QA SG 11202010841Q A SG11202010841Q A SG 11202010841QA
- Authority
- SG
- Singapore
- Prior art keywords
- anomeric
- alpha
- bicyclic sugar
- oligonucleotides conjugates
- sugar nucleosides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/337—Chemical structure of the base in alpha-anomeric form
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862670319P | 2018-05-11 | 2018-05-11 | |
PCT/EP2019/062064 WO2019215333A1 (en) | 2018-05-11 | 2019-05-10 | Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202010841QA true SG11202010841QA (en) | 2020-11-27 |
Family
ID=66530048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202010841QA SG11202010841QA (en) | 2018-05-11 | 2019-05-10 | Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230132377A9 (en) |
EP (1) | EP3790968A1 (en) |
JP (1) | JP2021522862A (en) |
KR (1) | KR20210008369A (en) |
CN (1) | CN112424352A (en) |
AU (1) | AU2019266550A1 (en) |
BR (1) | BR112020022620A2 (en) |
CA (1) | CA3098266A1 (en) |
SG (1) | SG11202010841QA (en) |
WO (1) | WO2019215333A1 (en) |
ZA (1) | ZA202007564B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3330276A1 (en) * | 2016-11-30 | 2018-06-06 | Universität Bern | Novel bicyclic nucleosides and oligomers prepared therefrom |
KR20210018267A (en) | 2018-05-07 | 2021-02-17 | 알닐람 파마슈티칼스 인코포레이티드 | Extrahepatic delivery |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
CA3108289A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
US20210308273A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US20220370491A1 (en) * | 2019-09-18 | 2022-11-24 | National University Corporation Tokyo Medical And Dental University | Nucleic acid complex |
AU2021382146A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
DE69031951T2 (en) | 1989-11-16 | 1998-08-13 | Cornell Res Foundation Inc | Transformation of animal skin cells with the help of particles |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
EP0552178B1 (en) | 1990-10-12 | 1997-01-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified ribozymes |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
KR100334858B1 (en) | 1993-02-19 | 2006-01-27 | 니뽄 신야쿠 가부시키가이샤 | Pharmaceutical Compositions Containing Nucleic Acid Copolymers |
TW404844B (en) | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
US6218108B1 (en) | 1997-05-16 | 2001-04-17 | Research Corporation Technologies, Inc. | Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor |
US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
JP2000325085A (en) * | 1999-05-21 | 2000-11-28 | Masafumi Matsuo | Pharmaceutical composition for treatment of duchenne muscular dystrophy |
US6653467B1 (en) * | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
US20080213891A1 (en) | 2004-07-21 | 2008-09-04 | Alnylam Pharmaceuticals, Inc. | RNAi Agents Comprising Universal Nucleobases |
US20090018097A1 (en) | 2005-09-02 | 2009-01-15 | Mdrna, Inc | Modification of double-stranded ribonucleic acid molecules |
EP3502255A1 (en) * | 2006-04-03 | 2019-06-26 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition |
US8501805B2 (en) * | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
CN103003288B (en) | 2010-05-28 | 2019-06-21 | 萨勒普塔医疗公司 | The oligonucleotide analogs of subunit linkage and/or end group with modification |
CN106581043A (en) * | 2016-10-24 | 2017-04-26 | 佳木斯大学 | Medicinal preparation suitable for Duchenne muscular dystrophy and preparation method thereof |
EP3330276A1 (en) * | 2016-11-30 | 2018-06-06 | Universität Bern | Novel bicyclic nucleosides and oligomers prepared therefrom |
-
2019
- 2019-05-10 CN CN201980046260.3A patent/CN112424352A/en active Pending
- 2019-05-10 WO PCT/EP2019/062064 patent/WO2019215333A1/en active Application Filing
- 2019-05-10 BR BR112020022620-3A patent/BR112020022620A2/en unknown
- 2019-05-10 SG SG11202010841QA patent/SG11202010841QA/en unknown
- 2019-05-10 JP JP2021513004A patent/JP2021522862A/en active Pending
- 2019-05-10 EP EP19723781.1A patent/EP3790968A1/en active Pending
- 2019-05-10 AU AU2019266550A patent/AU2019266550A1/en active Pending
- 2019-05-10 CA CA3098266A patent/CA3098266A1/en active Pending
- 2019-05-10 KR KR1020207034385A patent/KR20210008369A/en unknown
- 2019-05-10 US US17/054,724 patent/US20230132377A9/en active Pending
-
2020
- 2020-12-04 ZA ZA2020/07564A patent/ZA202007564B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210008369A (en) | 2021-01-21 |
US20230132377A9 (en) | 2023-04-27 |
CA3098266A1 (en) | 2019-11-14 |
AU2019266550A1 (en) | 2020-11-26 |
BR112020022620A2 (en) | 2021-02-17 |
EP3790968A1 (en) | 2021-03-17 |
US20220017898A1 (en) | 2022-01-20 |
ZA202007564B (en) | 2021-10-27 |
WO2019215333A1 (en) | 2019-11-14 |
JP2021522862A (en) | 2021-09-02 |
CN112424352A (en) | 2021-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202007564B (en) | Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides | |
IL288418A (en) | 4'-phosphate analogs and oligonucleotides comprising the same | |
IL273341A (en) | Substituted nucleosides, nucleotides and analogs thereof | |
SG11202106612QA (en) | Improved antibody-oligonucleotide conjugate | |
IL278990A (en) | Camptothecin conjugates | |
SG11202010496WA (en) | Anti-muc1 antibody-drug conjugate | |
IL295418A (en) | B-d-2'-deoxy-2'a-fluoro-2'-b-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment | |
IL269735A (en) | Antisense oligonucleotides for the treatment of stargardt disease | |
IL275950A (en) | Alpha-synuclein antisense oligonucleotides and uses thereof | |
GB201908583D0 (en) | Chocolate composition | |
IL276043A (en) | Process for the preparation of galnac oligonucleotide conjugates | |
IL270979A (en) | Precipitation resistant small molecule drug formulations | |
EP4038187A4 (en) | Oligonucleotides with nucleoside analogs | |
IL263852B (en) | Oligonucleotides comprising modified nucleosides | |
SG11202001495VA (en) | Spirothietane nucleosides | |
GB2590782B (en) | Tableware taking device | |
EP3743116C0 (en) | Radiolabelled oligonucleotides and process for their preparation | |
HK1256227A1 (en) | Modified nucleosides or nucleotides | |
GB201814450D0 (en) | Antisense oligonucleotides | |
HUP1700542A2 (en) | Nucleosides modified by 5'-linker | |
GB201815836D0 (en) | Nucleic acid conjugates | |
GB201811074D0 (en) | Nucleic acid conjugates | |
UA39819S (en) | "KOLECHKO GRILYAZHNE" CONFECTIONERY | |
SG10201807121QA (en) | Sugar Composition | |
UA35839S (en) | "PIVNYK" CANDY |